US FDA Grants Fast Track Designation for Paradigm's Phase 3 Osteoarthritis Program

US FDA Grants Fast Track Designation for Paradigm’s Phase 3 Osteoarthritis ProgramFDA Fast Track Designation for Pentosan Polysulfate Sodium (Zilosul™/PPS) offers pathways to expedite development of Paradigm’s osteoarthritis clinicalFDA Fast Track acknowledges osteoarthritis as a serious disease wi...

Related Keywords

Canada ,Australia ,Melbourne ,Victoria ,United Kingdom ,Donna Skerrett ,University Of Accessed ,Institute For Health ,Paradigm Biopharmaceuticals Ltd ,Paradigm Biopharmaceuticals ,Osteoarthritis Program ,Drug Administration ,Global Health Data Exchange ,Fast Track Designation ,Track Designation ,Pentosan Polysulfate Sodium ,Biopharmaceuticals Ltd ,Paradigm Chief Medical Officer ,Health Data Exchange ,Metrics Evaluation ,Accessed June ,Serious Disease ,Drug Administration December ,Patient Global Impression ,